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INTRODUCTION
The herpes simplex virus (HSV) thymidine kinase (TK) gene
is a suicide gene under study in both experimental and clin-
ical protocols as a treatment for human cancer. Transfer of the
TK gene into tumor cells results in tumor cell death upon
exposure to the antiviral prodrug ganciclovir (GCV), as the
TK protein phosphorylates the prodrug into a toxic nucleotide
analog whose incorporation into nascent DNA results in ter-
mination of DNA replication. Despite the in vivo HSV-TK
gene transduction of approximately 10-20% of tumor cells,
complete tumor eradication occurs in tumors (1). This phe-
nomenon is probably due to a ‘bystander effect’ associated
uniquely with the HSV-TK/GCV system. It includes the
transfer of the toxic metabolic products of GCV through gap
junction (2), which have recently been shown to be dependent
on connexin-mediated intercellular communication (3-5), the
phagocytosis of the apoptotic vesicles of dead tumor cells by
live tumor cells that mediate apoptosis (6) and the induction
of an immune response against the tumor (7-10).
In the present study, we first evaluated the bystander effect
in treating neuroblastoma, using HSV-TK transduced neuro-
2a cells as a model of neuroblastoma. Second, we examined
whether the mechanism of bystander effect in neuro-2a would
also depend on connexin-dependent gap junction and/or imm-
une response.
MATERIALS AND METHODS
Neuroblastoma Cell Lines
Neuro-2a, a subclone of C1300 murine neuroblastoma A/J
mice (American Type Culture Collection, Rockville, MD,
U.S.A.), was cultured in modified Eagle medium (GIBCO,
Grand Island, NY, U.S.A.) supplemented with 100  g/mL
streptomycin (GIBCO), 100 U/mL penicillin (GIBCO), and
with 10% heat-inactivated fetal bovine serum (GIBCO).
PA317 is an amphotropic packaging line derived from NIH
3T3 TK- cells transfected with helper plasmid pPAM3. The
ecotropic retrovirus packaging cell line PSI-CRE used here
contains split helper virus genomes that reduce potential for
helper virus generation. Cells were grown in Dulbecco’ s mod-
ified Eagle medium (GIBCO), supplemented with 4.5 g/L
glucose and 10% fetal bovine serum.
Retroviral Vectors
The HSV-TK gene containing an internal ribosome entry
site (IRES) fragment of encephalomyocarditis virus was sub-
cloned in the HpaI site of LNCX retroviral vector as a 1.7-kb
BamHI-XhoI insert isolated from the pSXLC-TK after fill-
ing-in with Klenow enzyme, resulting in a HSV-TK express-
ing retroviral vector LNC/IRES/TK. PA317 cells were plated
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Bystander-Mediated Regression of Murine Neuroblastoma via 
Retroviral Transfer of the HSV-TK Gene
Selective introduction of genes conferring chemosensitivity into proliferating tumor
cells may be used to treat cancer. We investigated the bystander effect of retrovirus-
mediated gene transfer of herpes simplex virus thymidine kinase (HSV-TK) gene
to murine neuroblastoma cell line (neuro-2a) in vitro and in vivo, and we examined
whether the mechanism of bystander effect in neuroblastoma would also depend on
connexin-dependent gap junction and/or immune response. A strong bystander effect
was observed in vitro, whereby nontransduced tumor cells in proximity to transduced
cells acquired susceptibility to ganciclovir (GCV) killing. Implanted mixtures of wild-
type cells and HSV-TK transduced cells showed a potent bystander effect upon ad-
ministration of GCV in A/J mice. HSV-TK/GCV system in murine neuroblastoma
induced systemic immunity. Immunohistochemical staining showed many CD4+
and CD8+ cell infiltration but did not show anti-connexin 43+ cells. In conclusion, a
strong bystander effect was observed in vitro and in vivo. The bystander effect in
murine neuroblastoma might be dependent on immune response and/or on other
mechanism such as protein phosphorylation or transfer of apoptotic vesicle, rather
than connexin-dependent gap junction.
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at 1×105 cells per 60-mm dish one day prior to virus expo-
sure. On the day of infection, 1 mL of serially diluted culture
medium harvested from the PSI-CRE clonal cell line produc-
ing ecotropic virus vector (LNC/IRES/TK) was plated in the
presence of 8  g/mL polybrene for 4 hr. Culture medium was
changed and G418-resistant colonies were selected. Virus pro-
ducing cell lines producing high-titer (>1×107 cfu/mL) retro-
viral vectors were designated PA317/LNC/IRES/TK and were
used as sources of recombinant retroviral vectors for transduc-
tion of neuro-2a cells.
In Vitro Experiments
For in vitro infection, neuro-2a cells were incubated for 4
hr at 37℃in the presence of 8  g/mL polybrene with filtered
supernatant from retroviral producer cells (PA317/LNC/
IRES/TK). After the supernatant was changed with fresh
medium, the cells were incubated for another 48 hr before
changing into selection media that contained 500  g/mL
G418 (Geneticin, GIBCO). Isolated clones were picked 14
days later, analyzed for sensitivity to GCV (Cymevene, Syn-
tex Laboratories, Inc., Palo Alto, CA, U.S.A.) and were des-
ignated neuro-2a/TK. For the in vitro HSV-TK bystander
assay, 1×106 cells were plated in triplicate into 6-well plates
as follows: 100% transduced and 100% untransduced cells
and mixtures of transduced and untransduced cells at ratios
of 1:1 and 1:10, and 1:20. After 24 hr of incubation, cells were
exposed to 10  g/mL GCV in medium. Medium was exch-
anged every other day. On day 1, day 2, day 3 and day 4, sur-
viving cells were counted by trypan blue exclusion method.
In Vivo Experiments
A/J mice, 6-10 weeks of age, were obtained from Yonsei
Clinical Research Center (Seoul, Korea). For tumor cell implan-
tation, cells were enzymatically detached from culture flasks
and counted. 2×106 cells were resuspended in 100  L of ser-
um-free medium and were injected subcntaneously (s.c.) into
the flank as follows: 100% HSV-TK-transduced (Group 1),
100% untransduced cells (Group 2) and mixtures of trans-
duced and untransduced cells at ratios of 1:1 (Group 3), 1:10
(Group 4) and 1: 20 (Group 5). Tumor measurements were
performed at least once a week with calipers. When the tumors
reached the diameter of 5-8 mm, the animals were random-
ly assigned to treatment groups (N=8/group), and the mice
received 50 mg/kg GCV intraperitoneally twice a day for 7
days. Animals were monitored for 50 days.
To examine the induction of an immune response against
the tumor, 2×106 HSV-TK cells and 2×106 neuro-2a cells
injected s.c. into the flank of the mice, respectively (N=6/
group). Seven days after tumor cells challenge, the mice received
50 mg/kg GCV intraperitoneally twice a day for 7 days, and
then the animals were challenged by s.c. implantation of
approximately 2×106 unmodified neuro-2a cells contralat-
erally to the original injection sites 14 days after the last GCV
treatment. The survival rate was monitored weekly for 50 days.
Statistical analysis was done by log rank test.
Histochemical Staining
In Group 5, the tumor which was established with 25%
HSV-TK-positive cells were dissected, embedded in paraffin,
and were cut into 4  m sections. We stained the tumor tissue
with mouse anti-connexin 43 monoclonal antibody (Chemi-
con International, Inc., Temecula, CA, U.S.A.). And the sub-
cutaneous tissue of the tumor-regressed site which was inject-
ed with 25% HSV-TK-positive cells and followed by GCV
treatment were dissected after the tumor reduced completely
and the sample were embedded in paraffin, cut into 4  m sec-
tions. The primary antibodies used in the immunohistochem-
istry were goat polyclonal antibodies to cell membrane of CD4,
rabbit polyclonal antibodies to cell membrane of CD8 (Santa
Cruz Biotechnology, Inc., Santa Cruz, CA, U.S.A.). The slide
were stained with horseradish-peroxidase-linked streptavidin
(DAKO, Carpinteria, CA, U.S.A.), and then counterstained
by Mayer hematoxylin.
RESULTS
In Vitro Bystander Effect
The survival of the mixtures containing 0, 5, 10, 50, 100%
HSV-TK-positive cells which were incubated with 10  g/mL
GCV for 4 days was 142%, 53%, 0%, 0%, respectively. These
findings suggest that the bystander effect is significant in HSV-
TK-expressing cells (Fig. 1).
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Fig. 1. In vitro bystander assay. Wild type neuro-2a cells and neuro-
2a/TK cells were mixed at varying ratios, plated in 6 well culture
plates (10
6/cell), and incubated at 37℃ overnight. Cells were ex-
posed to GCV (10  g/mL). On day 1, day 2, day 3 and day 4, cells
were stained with trypan blue and surviving cells were enumerated.
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In Vivo Bystander Effect
To assess the bystander effect, when the tumors reached the
diameter of 5-8 mm, the animals were randomly assigned to
treatment groups, and the mice received 50 mg/kg GCV in-
traperitoneally twice a day for 7 days. In Groups 1 and 3, the
sizes of the tumors decreased when followed by a course of
GCV, and all tumors regressed completely at 5 days and at 7
days after GCV treatment, respectively. The survival rate at
50 days was 100% in both groups. In Group 4, the growth
of the tumor delayed during the GCV treatment and the sur-
vival rate at 50 days was 25% (Fig. 2).
None of the mice, which treated by GCV after 100% HSV-
TK cell injection and received the second tumor cell challenges,
developed the tumor at the site of challenge of unmodified
neuro-2a cells during the observation period. In contrast, all
of the mice of the control group developed tumors. These results
support that the death of HSV-TK positive cells by GCV treat-
ment elicit an anti-tumor immune response (Fig. 3).
Histochemical Staining
Immunohistochemical staining showed a migration of
CD4+(Fig. 4A) and CD8+cells into the tumor, which inject-
ed with 25% HSV-TK-positive cells and followed by GCV
treatment (Fig. 4B). However, the murine neuroblastoma did
not show anti-connexin 43+ cells (Fig. 4C).
DISCUSSION
With current gene transfer techniques, more than 10% trans-
fection efficiency can be obtained in the vicinity of the gene
transfer site in vivo (11). However, the overall transfection effi-
ciency in human tumor models is still very low because the
number of cells in the vicinity of the transfection site is low
compared with the total tumor mass (11). Accordingly by-
stander effect in HSV-TK gene therapy gives great advantages
in tumor treatment.
In this study we used the syngenic neuroblastoma model
in A/J mice. Mice in Groups 1 and 3 were followed for up to
100 days without tumor recurrence. Significantly prolonged
survival in animals which were injected with more than 50%
HSV-TK-positive cells and followed by GCV treatment was
observed. Our results show that, both in vitro and in vivo, more
than 10% HSV-TK-transduced cells among wild type neuro-
2a cells are required for a beneficial GCV treatment effect. The
results are in line with other tumor models previously pub-
lished (3, 12, 13) and indicate that the bystander effect also
occurs in the murine neuroblastoma cells. Our results confirm
the important role of the bystander effect in the treatment of
experimental neuroblastoma. This bystander effect has impor-
tant clinical implications, in that the HSV-TK gene need not
be delivered to all malignant cells and may operate over a dis-
tance. However, there are also reports indicating that HSV-
TK gene transfer followed by GCV treatment does not lead
to a complete eradication of other experimental tumor (14).
The reason for the discrepancy in HSV-TK/GCV results is
currently unclear, but may involve different cell lines or con-
ditions used for the gene transfer and GCV treatment. Also,
the differences in tissue reactions in various experimental tumor
models probably affect the final outcome (15-17).
The mechanism of the bystander effect is still under inves-
tigation. It appears to be enhanced by cell-to-cell contact and
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Fig. 2. In vivo bystander effect. 2×10
6 cells were injected s.c. into
the flank as follows: 100% HSV-TK-transduced (Group 1) and 100
% untransduced cells (Group 2) and mixtures of transduced and
untransduced cells at ratios of 1:1 (Group 3), 1:10 (Group 4) and
1:20 (Group 5). When the tumors reached the diameter of 5-8 mm,
the mice received intraperitoneally 50 mg/kg GCV twice a day for
7 days. Group 2 versus Group 1: significant, p<0.01; Group 2 ver-
sus group 3: significant, p<0.01; Group 2 versus Group 4: signif-
icant, p<0.01; Group 2 versus Group 5: significant, p<0.05 (log
rank test).
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Fig. 3. Induction of immune response in HSV-TK gene-transduced
neuro-2a cells. 2×10
6 HSV-TK cells (Group 1) and 2×10
6 neuro-
2a cells (Group 2) injected s.c. into the flank of the mice, respec-
tively (N=6/group). One week after tumor cell challenge, the mice
received intraperitoneally 50 mg/kg GCV twice a day for 7 days and
then the animals were challenged by s.c. implantation of approxi-
mately 2×10
6 unmodified neuro-2a cells contralaterally to the origi-
nal injection sites 14 days after the last GCV treatment. Log rank
test showed group  survived significantly compared with Group 2
(p<0.01).
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by the presence of gap junctions, which are composed of con-
nexin, a family of homologous proteins expressed in cell- and
tissue-specific patterns. There are close correlations between
tumor cell gap junctional intercellular communication and
the magnitude of the HSV-TK bystander effect. Tumors not
expressing connexin at all will be ineffective in bystander effect
(18, 19). Indeed, the bystander effect is likely to be phospho-
rylated GCV that enters TK-cells through cellular junction.
The uptake of phosphorylated GCV released from apoptotic
cells may also contribute to the bystander effect. Apoptosis
seems to be an important mechanism for cell death, as also
demonstrated by others (20, 21). However, Dahle et al. (22)
reported that bystander effect was not mediated by gap junc-
tional intercellular communication but protein phosphoryla-
tion is important in cellular signaling pathways and may be
involved in the bystander effect, for example by influencing
the mode of cell death. In our experiment we did not observed
the connexin 43 expression on murine neuroblastoma model.
Andrade-Rozental et al. (23) also demonstrated that neuro-2a
cells are expressed very low endogenous level of gap junction-
al communication. This result indicates that the bystander
effect in murine neuroblastoma depends on other mechanism
such as the phagocytosis of the apoptotic vesicles of dead tumor
cells by live tumor cells or the induction of an immune response
against the tumor rather than connexin-dependent gap junc-
tion.
We have shown that significant anti-tumor immunity does
develop following HSV-TK and GCV treatments of murine
Fig. 4. Expression of CD 4, CD 8 and connexin-43 antigen. Paraffin-
embedded sections were reacted with goat polyclonal antibodies
to CD4 (A), rabbit polyclonal antibodies to CD8 (B) and not react-
ed with mouse anti-connexin 43 antibody (C). (A, B) Cell membrane
staining of subcutaneous tissue of the tumor-regressed site. Mag-
nification was at ×1,000. (C) Solid area of neuroblastoma before
GCV. Magnification was at ×400.
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Bneuroblastoma. Barba et al. (9) suggested that HSV-TK and
GCV treatment of brain tumor induced the significant anti-
tumor immune response. We suggest that, in immunogenic
tumor, the immune system participates in maintaining long-
term tumor regression and induces the development of by-
stander effect (24-26). The development of anti-tumor immu-
nity following HSV-TK and GCV treatment could be used
in tumor vaccination strategies. The emergence of a protective
immunity against the parental tumor cells might be with the
appearance of tumor-specific cytotoxic T cells or APCs derived
from mice following HSV-TK and GCV treatment and con-
tinue for a long time.
These observations suggest the use of cytokines to the nat-
ural immune response as a potential cancer therapy, and the
long-term survival could be improved by stimulation of an
immune response toward inoculated tumor cells (12). In the
future the stimulation of inflammatory and immunological
reactions by combined gene transfer of HSV-TK and cytokines
such as interleukin-2 (IL-2), IL-3, IL-12, or granulocyte macro-
phage colony stimulating factor might improve the effec-
tiveness of the HSV-TK/GCV treatment in neuroblastoma
model, especially when only low transfection efficiencies can
be obtained.
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